SEC Form 4 · accession 0001179110-15-016040
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John F Milligan
Officer — President and COO
Period of report
Dec 7, 2015
Accepted (ET)
Dec 9, 2015 · 2:14 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 7, 2015 | M | 100,000 | $14.5025 | A | 1,129,108 | D | |
| Common StockF3 | Dec 7, 2015 | S | 60,645 | $102.9349 | D | 1,068,463 | D | |
| Common StockF4 | Dec 7, 2015 | S | 39,355 | $103.5571 | D | 1,029,108 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2 | $14.5025 | Dec 7, 2015 | M | 100,000 | D | — | Jan 25, 2016 | Common Stock | 100,000 | 0 | D |
Explanation of responses
- F1The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- F2The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
- F3Sale prices reported for the transactions reported here range from $102.27 to $103.27. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- F4Sale prices reported for the transactions reported here range from $103.275 to $104.15. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.